BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28502936)

  • 1. Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation.
    Nakamura Y; Matsuguma M; Tokunaga Y; Yamamoto K; Tanaka M; Tanaka Y; Yujiri T; Tanizawa Y
    Intern Med; 2017; 56(10):1199-1202. PubMed ID: 28502936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.
    Tanaka H; Shimizu N; Tougasaki E; Kawajiri C; Hashimoto S; Takeda Y; Sakai S; Takeuchi M; Ohwada C; Sakaida E; Takagi T; Nakaseko C
    Int J Hematol; 2013 Apr; 97(4):520-4. PubMed ID: 23519573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
    Drozd-Sokołowska J; Karakulska-Prystupiuk E; Biecek P; Kobylińska K; Piekarska A; Dutka M; Waszczuk-Gajda A; Mądry K; Kopińska A; Gołos A; Góra-Tybor J; Szwedyk P; Bołkun Ł; Czyż A; Giebel S; Basak GW; Dwilewicz-Trojaczek J
    Eur J Haematol; 2021 Jul; 107(1):129-136. PubMed ID: 33764578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
    Platzbecker U; Wermke M; Radke J; Oelschlaegel U; Seltmann F; Kiani A; Klut IM; Knoth H; Röllig C; Schetelig J; Mohr B; Graehlert X; Ehninger G; Bornhäuser M; Thiede C
    Leukemia; 2012 Mar; 26(3):381-9. PubMed ID: 21886171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
    Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
    Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
    Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
    Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
    Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
    Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
    Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
    Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
    Vij R; Le-Rademacher J; Laumann K; Hars V; Owzar K; Shore T; Vasu S; Cashen A; Isola L; Shea T; DeMagalhaes-Silverman M; Hurd D; Meehan K; Beardell F; Devine S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1984-1992. PubMed ID: 31212080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
    Omatsu T; Udaka K; Shibata H; Sekimoto E; Ozaki S
    Rinsho Ketsueki; 2017; 58(12):2369-2374. PubMed ID: 29332868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
    Schroeder T; Kobbe G
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1703-4. PubMed ID: 26277403
    [No Abstract]   [Full Text] [Related]  

  • 17. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
    Maples KT; Sabo RT; McCarty JM; Toor AA; Hawks KG
    Leuk Lymphoma; 2018 Dec; 59(12):2836-2841. PubMed ID: 29616863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
    Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
    Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia with intestinal Behçet's disease: A case report.
    Liu C; Fu C; Guo X; Rong L; Li J; Fang Y
    Int J Rheum Dis; 2024 Jan; 27(1):e14882. PubMed ID: 37771000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.